Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Biocon Limited ( (IN:BIOCON) ) has shared an announcement.
Biocon’s board has approved its audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, alongside recommending a final dividend of 10%, or Rs 0.50 per share, with a record date of 3 July 2026 and payment due by 31 August 2026. The board also proposed appointing S. R. Batliboi & Associates LLP as the new statutory auditor, redesignated two senior executives as senior management, and reshaped its board with key independent and non-executive appointments to support integration with subsidiary Biocon Biologics and advance its strategy of building a unified global biopharmaceutical leader.
More about Biocon Limited
Biocon Limited is an India-based biopharmaceutical company headquartered in Bengaluru, focused on developing and manufacturing biosimilars, novel biologics and active pharmaceutical ingredients for global markets. The company serves both emerging and developed markets, positioning itself as a significant player in cost-effective biologic therapies and complex generics.
Average Trading Volume: 216,783
Technical Sentiment Signal: Buy
Current Market Cap: 616.6B INR
See more data about BIOCON stock on TipRanks’ Stock Analysis page.